Medtronic Gets FDA OK To Start Pivotal Trial Of CoreValve
This article was originally published in The Gray Sheet
Executive Summary
Medtronic has gained conditional approval from FDA to begin the pivotal trial of its CoreValve transcatheter aortic valve system in the United States, the firm announced Oct. 15.
You may also be interested in...
News In Brief
Roche’s melanoma companion diagnostic approved
News In Brief
Roche’s melanoma companion diagnostic approved
FDA OKs Sapien Valve As Pivotal Trial Control Prior To Marketing Approval
Edwards Lifesciences says FDA will support use of the firm's investigational Sapien transcatheter aortic heart valve as a control treatment in an upcoming trial of the firm’s next-generation Sapien XT.